We are focused on developing first in class therapeutics for a range of targets involved in autoinflammation, oncology, and infectious disease. 

What We Do_thompson lab.png

We develop potent and selective inhibitors of proteins whose activities are involved in triggering human diseases.

 

Why We Do It_generic.png

Diseases like rheumatoid arthritis and cancer affect millions every year, and our studies could help alleviate human suffering by identifying new drugs.

How We Do It_thompson lab.png

Our lab uses kinetic and structural analyses to guide the design of small molecule inhibitors, which we then synthesize and evaluate as inhibitors.

Who We Are_generic.png

We are a highly collaborative and social group of dedicated chemists and biologists.

 

Research Highlights

Chemical Biology of Protein Arginine Modifications in Epigenetic Regulation

Fuhrmann, J., Clancy, K., Thompson, P.R. (2015) Chemical Biology of Protein Arginine Modifications in Epigenetic Regulation. Rev. 115 , 5413-5461.  PMC4463550

Targeting STING oligomerization with small-molecule inhibitors

Humphries, F., Shmuel-Galia, L., Jiang, Z., Zhou, J., Barasa, L., Mondal, S., Wilson, R, Sultana, N., Shaffer, S.A., Ng, S., Pesiridis, G.S., Thompson, P.R.* and Fitzgerald, K.A. * (2023) Targeting STING oligomerization with small-molecule inhibitors.  PNAS 120, e2305420120.  


Dual Inhibitors of Main Protease (MPro) and Cathepsin L as Potent Antivirals against SARS-CoV2

Mondal, S., Chen, Y., Lockbaum, G.J., Sen, S., Chaudhuri, S. Reyes, A.C., Lee, J.M., Kaur, A.N., Sultana, N. Cameron, M.D., Shaffer, S.A., Schiffer, C.A., Fitzgerald, K.A., and Thompson, P.R. (2022) Dual Inhibitors of Main Protease (MPro) and Cathepsin L as Potent Antivirals against SARS-CoV2. J. Am Chem Soc. 144, 21305-21045. PMID: 36356199. PMC9662648  

Site-specific incorporation of citrulline into proteins in mammalian cells

Mondal, S., Wang, S., Zheng, Y., Sen, S., Chatterjee, A., and Thompson, P. R. (2021) Site-Specific Incorporation of Citrulline into Proteins in Mammalian Cells. Nature Comm.  12, 45.  PMID: 33398026

Thompson Lab News

  • bmb blog resized sting.png
    Sep 15, 2023

    Taking the STING out of Disease -Biochemistry & Molecular Biotechnology (BMB) Department

    Dr. Paul Thompson of the Biochemistry & Molecular Biotechnology department at UMass Chan Medical School recently published a newly discovered inhibitor of STING signaling that could be a promising new treatment option for various diseases including lupus, SAVI, and ALS.

    Read more
  • bmb blog resized PAD.png
    Mar 6, 2023

    BMB highlights research on PAD enzymes for Autoimmune Disease Awareness Month

    For Autoimmune Disease Awareness Month, we are featuring the work of Dr. Paul Thompson in our department. The goal of his research is to develop drugs to inhibit a family of proteins called PAD's that play a major role in the pathology of many different autoimmune diseases.

    Read more

Thompson Lab Social Media

Page Menu